UTHR United Therapeutics Corporation
Healthcare$578.43+1.76%ClosedMarket Cap: $24.55B
As of 2026-05-26
Valuation
P/E (TTM)
18.58
PEG
1.59
P/B
4.19
P/S
7.61
EV/EBITDA
13.42
DCF Value
$782.02
FCF Yield
4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.6%
Operating Margin
45.3%
Net Margin
40.6%
ROE
19.2%
ROA
19.2%
ROIC
18.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $781.5M | 82.9% | $325.8M | $274.9M | $— | — |
| Q4 null | $790.2M | 86.9% | $357.5M | $364.3M | $— | — |
| FY null | $3.18B | 87.9% | $1.52B | $1.33B | $— | — |
| Q3 null | $799.5M | 87.4% | $389.3M | $338.7M | $— | — |
| Q2 null | $798.6M | 89.0% | $364.5M | $309.5M | $— | — |
| Q1 null | $794.4M | 88.4% | $382.8M | $322.2M | $— | — |
| Q4 null | $735.9M | 89.7% | $357.7M | $301.3M | $— | — |
| FY null | $2.88B | 89.2% | $1.38B | $1.20B | $— | — |
| Q3 null | $748.9M | 88.9% | $343.1M | $309.1M | $— | — |
| Q2 null | $714.9M | 89.1% | $319.9M | $278.1M | $— | — |
| Q1 null | $677.7M | 89.2% | $356.3M | $306.6M | $— | — |
| Q4 2023 | $614.7M | 88.4% | $260.1M | $217.1M | $4.36 | — |